Post by
consultant99 on Apr 05, 2022 1:28pm
What Matters
The company stated;
Study II has delivered significant clinical results to date for the primary, secondary and tertiary objectives.
Research Capital agrees and has raised their Target Price from $0.70 to $1.20 Cdn
Comment by
Lesalpes29 on Apr 05, 2022 1:32pm
Easy to forget that the NR today was a positive one. Thank for posting the 1.20 target price. Let's go buyers!
Comment by
ggrellette on Apr 05, 2022 1:37pm
The news was a huge disappointment to the market and that is evident in the collapse of the share price.
Comment by
RoseHeaven on Apr 05, 2022 1:39pm
“From the 38 patients treated to date in Study II, those evaluable patients, have achieved 50.0% CR at 90 days and 25.0% have maintained this CR for at least 450 days, since primary study treatment.
Comment by
FGPstock on Apr 05, 2022 1:56pm
Consulant, did you see research capital reaffirm this price today? i didnt see it in the release...
Comment by
consultant99 on Apr 05, 2022 3:14pm
The up-grade in the Target Price by Research Capital was made in their latest TLT report; it was not in the TLT press release.